We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » TB Trials Must Reflect Properties of Experimental Drugs
TB Trials Must Reflect Properties of Experimental Drugs
July 15, 2008
Patient recruitment and other aspects of tuberculosis (TB) clinical trials must be tailored to the properties of the agent being tested, according to a draft guideline from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor